The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Physiomics Optimistic On Virtual Tumour Platform Interest

Wed, 12th Nov 2014 10:47

LONDON (Alliance News) - Physiomics PLC Wednesday said that interest in its Virtual Tumour platform "suggest that the next period will be an exciting one in the development of Physiomics", as it posted a slightly narrowed loss in its year to end-June.

The company posted a pretax loss of GBP464,252, narrowed slightly from GBP543,791 a year before, as revenue rose to GBP267,903 from GBP240,000.

Physiomics is working on commercialising what it considers its tent-pole product, the Virtual Tumour Clinical platform, a technology that uses a mathematical model to predict the growth of tumours.

During the period the company saw a "large degree" of interest from customers and potential customers for the service, it said. Physiomics noted that the product can be used to design a clinical study, and given the "high cost and subsequent consequences arising from a failed clinical trial", if it can show that its predictive technology can improve the chances of a success, customers are "likely to progressively adopt the new paradigm".

During the period Physiomics delivered two case studies validating the platform, and won further pre-clinical projects from its existing larger pharmaceutical company customer base.

It has continued discussions with partners about increasing the scope of its business via merger or acquisition, and began discussions with an undisclosed software provider to determine if part or all of Virtual Tumour could be sold as part of their offering.

Following the year end the company won a large pharma project to model immunomodulatory agents using Virtual Tumour, which it believes if successful will lead to further interest in the platform.

"Interest from large software providers in the Virtual Tumour platform, the launch of our first web-based models and the continued search for the right M&A deal suggest that the next period will be an exciting one in the development of Physiomics," the company said in a statement.

Shares in Physiomics are trading down 9.3% at 0.136 pence Wednesday morning.

By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews

Copyright 2014 Alliance News Limited. All Rights Reserved.

Related Shares

More News
3 May 2024 14:34

IN BRIEF: Physiomics warns large contracts taken longer than expected

Physiomics PLC - Milton Park, England-based data science company, focused on new therapeutics and personalised medicine solutions - Warns several larg...

3 May 2024 11:21

Physiomics lowers forecasts amid contract delays

(Sharecast News) - Therapeutics and medicine-focussed mathematical modelling and data science company Physiomics said in an update on Friday that, des...

3 May 2024 10:52

AIM WINNERS & LOSERS: Fletcher King optimistic; Angle in Astra deal

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

18 Mar 2024 11:57

IN BRIEF: Physiomics celebrates "substantial" contract with old client

Physiomics PLC - mathematical modelling company that supports oncology drug development - Receives a "substantial" new contract by an existing "large ...

18 Mar 2024 09:43

Physiomics secures 'substantial new contract' with existing pharma client

(Sharecast News) - Mathematical modelling and data science company Physiomics has been awarded "a substantial new contract" by an existing large pharm...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.